In this incurable world, there are plethora of diseases which were not cured by many remarkable therapies but after R3 stem cell therapy was introduced, whole scenario was changed. With a third of the US suffering from chronic pain, and over a million each year undergoing joint replacements in the US, regenerative therapies have a large target audience. R3 Stem Cell has achieved Institutional Review Board (IRB) Approval for the investigation of regenerative therapies including orthopedic and autoimmune conditions. See the specifics on ClinicalTrials.gov
Topics
